Novogene Co., Ltd. Stock

Equities

688315

CNE1000052X3

Healthcare Facilities & Services

End-of-day quote Shanghai S.E. 18:00:00 2024-04-25 EDT 5-day change 1st Jan Change
13.57 CNY +2.18% Intraday chart for Novogene Co., Ltd. +5.93% -41.86%

Financials

Sales 2024 * 2.33B 322M 440M Sales 2025 * 2.78B 384M 525M Capitalization 5.6B 773M 1.06B
Net income 2024 * 213M 29.4M 40.19M Net income 2025 * 261M 36.02M 49.24M EV / Sales 2024 * 2.4 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 2.01 x
P/E ratio 2024 *
26.6 x
P/E ratio 2025 *
21.7 x
Employees 2,144
Yield 2024 *
0.74%
Yield 2025 *
1.33%
Free-Float 22.59%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.18%
1 week+5.93%
Current month-4.03%
1 month-3.83%
3 months-23.33%
6 months-38.74%
Current year-41.86%
More quotes
1 week
12.56
Extreme 12.56
13.63
1 month
12.50
Extreme 12.5
14.66
Current year
12.17
Extreme 12.17
23.56
1 year
12.17
Extreme 12.17
35.70
3 years
12.17
Extreme 12.17
69.82
5 years
12.17
Extreme 12.17
69.82
10 years
12.17
Extreme 12.17
69.82
More quotes
Managers TitleAgeSince
Chief Executive Officer 44 11-03-14
Director of Finance/CFO 42 14-03-31
Director/Board Member 46 12-01-31
Members of the board TitleAgeSince
Chief Executive Officer 44 11-03-14
Director/Board Member 46 12-01-31
Director/Board Member 44 22-06-14
More insiders
Date Price Change Volume
24-04-26 13.57 +2.18% 2,515,826
24-04-25 13.28 +0.30% 2,197,605
24-04-24 13.24 -0.90% 2,317,626
24-04-23 13.36 +2.61% 2,013,110
24-04-22 13.02 +1.64% 1,544,890

End-of-day quote Shanghai S.E., April 25, 2024

More quotes
Novogene Co Ltd is a China-based company principally engaged in gene sequencing. The Company mainly relies on high-throughput sequencing technology and bioinformatics analysis technology to establish gene sequencing platforms. Combined with multi-omics research technology, the Company provides multi-level scientific and research technical services and solutions for life science basic research, medical and clinical application research. Based on the technology accumulation in gene sequencing and its application fields, the Company independently develops genetic testing medical equipment. The Company's services mainly include life science basic scientific research services, medical research and technical services, and database-building sequencing platform services. Its other services and products include gene mutation detection kits, coronavirus disease nucleic acid test service and DA8600 sequencers. The Company conducts its businesses in domestic and overseas markets.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
13.57 CNY
Average target price
21.48 CNY
Spread / Average Target
+58.31%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 688315 Stock